A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.

Autor: Soczynska JK; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Kennedy SH; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Alsuwaidan M; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, Kuwait University, Kuwait City, Kuwait., Mansur RB; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Li M; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Psychosocial Oncology Clinic, University Health Network, Toronto, ON, Canada., McAndrews MP; Department of Psychology, University of Toronto, Toronto, ON, Canada.; Neuropsychology Clinic, University Health Network, Toronto, ON, Canada., Brietzke E; Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Department of Psychiatry, Federal University of São Paulo, São Paulo, Brazil., Woldeyohannes HO; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Taylor VH; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, Women's College Hospital, Toronto, ON, Canada., McIntyre RS; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Department of Toxicology and Pharmacology, University of Toronto, Toronto, ON, Canada.

Publikováno v: Bipolar disorders [Bipolar Disord] 2017 May; Vol. 19 (3), pp. 198-213.

Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.

Autor: Mansur RB; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil. Electronic address: rodrigomansur71@uol.com.br., Ahmed J; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada., Cha DS; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada., Woldeyohannes HO; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada., Subramaniapillai M; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada., Lovshin J; Division of Endocrinology, Mount Sinai Hospital, University of Toronto, Toronto, Canada., Lee JG; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea., Lee JH; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada; Department of Psychiatry, Samsung Seoul Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea., Brietzke E; Research Group in Molecular and Behavioral Neuroscience of Bipolar Disorder, Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil., Reininghaus EZ; Medical University of Graz, Department of Psychiatry, Graz, Austria., Sim K; Research Division, Institute of Mental Health, Singapore., Vinberg M; Psychiatric Center Copenhagen, University of Copenhagen, Copenhagen, Denmark., Rasgon N; Department of Psychiatry, Stanford University, Palo Alto, CA, United States., Hajek T; Department of Psychiatry, Dalhousie University, Halifax, Canada., McIntyre RS; Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada.

Publikováno v: Journal of affective disorders [J Affect Disord] 2017 Jan 01; Vol. 207, pp. 114-120. Date of Electronic Publication: 2016 Oct 01.

Binge eating in adults with mood disorders: Results from the International Mood Disorders Collaborative Project.

Autor: Woldeyohannes HO; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Soczynska JK; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada., Maruschak NA; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Syeda K; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Wium-Andersen IK; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Lee Y; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Cha DS; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada., Xiao HX; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Gallaugher LA; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Dale RM; Cleveland Clinic, Cleveland, OH, USA., Alsuwaidan MT; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Mansur RB; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Muzina DJ; Turn2Health Solutions, Willoughby, OH, USA., Carvalho AF; Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Fortaleza, Brazil., Jerrell J; Department of Neuropsychiatry, University of South Carolina School of Medicine, USA., Kennedy S; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada., McIntyre RS; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Department of Pharmacology, University of Toronto, Toronto, ON, Canada. Electronic address: roger.mcintyre@uhn.ca.

Publikováno v: Obesity research & clinical practice [Obes Res Clin Pract] 2016 Sep - Oct; Vol. 10 (5), pp. 531-543. Date of Electronic Publication: 2015 Oct 24.

A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect.

Autor: Lee Y; From the *Mood Disorders Psychopharmacology Unit, University Health Network; †Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; ‡Psychiatric Center Copenhagen, Department O, Copenhagen, Denmark; and Departments of §Psychiatry and ∥Pharmacology, University of Toronto, Toronto, Ontario, Canada., Syeda K, Maruschak NA, Cha DS, Mansur RB, Wium-Andersen IK, Woldeyohannes HO, Rosenblat JD, McIntyre RS

Publikováno v: Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2016 Feb; Vol. 36 (1), pp. 50-6.

The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project.

Autor: McIntyre RS; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada. Electronic address: roger.mcintyre@uhn.ca., Soczynska JZ; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Woldeyohannes HO; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Alsuwaidan MT; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Cha DS; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Carvalho AF; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Jerrell JM; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Dale RM; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Gallaugher LA; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Muzina DJ; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada., Kennedy SH; Psychiatry and Pharmacology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.

Publikováno v: Comprehensive psychiatry [Compr Psychiatry] 2015 Jan; Vol. 56, pp. 279-82. Date of Electronic Publication: 2014 Aug 23.